Skip to main content

03-04-2019 | Mental health | Editorial | Article

Diabetes and dementia: Addressing the needs of an overlooked population

Author: Amar Puttanna

Author bio | Disclosures

Diabetes and dementia are on the rise. Projections for the UK suggest that by 2025, 5 million people will have diabetes (90% with type 2 diabetes) and 1 million people will have dementia. The UK government has singled out diabetes and dementia conditions independently as key areas to target moving forward. In addition, there is also a push to manage “multimorbidity” and deal with the complexities of an aging population. It is therefore surprising that the combination of diabetes and dementia is not attracting more attention among clinicians, researchers and policy makers.

Current research

Clinical research is still in the initial stages of unravelling the relationship between cognitive impairment and diabetes. However, there is epidemiological evidence indicating that people with diabetes are at twice the risk of developing dementia than those without diabetes. Given the early state of research it is unsurprising to find that a number of mechanisms have been postulated to account for the association between cognitive impairment and diabetes. The leading theories are summarized in the table below:

Proposed diabetes–dementia mechanistic links

Type 3 diabetes mellitus/Alzheimer’s disease 
Insulin resistance in the brain leads to tau protein formation and the subsequent amyloid plaque formation associated with Alzheimer’s disease.

Cerebrovascular disease 
Diabetes increases the risk of atherosclerotic disease and changes to chronic small vessel changes, contributing to cerebrovascular disease and increasing the risk of cognitive decline.

Episodes of low blood sugar contribute to cognitive decline via an, as yet, unknown mechanism.

It could be argued that cognitive impairment should be among the recognized list of “diabetes complications”. Indeed, there is a gap in research for long-term diabetes trials to incorporate data on cognitive impairment into their outcomes. Data on glycated hemoglobin (HbA1c) and its link to cognitive impairment appears to support this assertion, as the English Longitudinal Study of Ageing demonstrated that increasing HbA1c is associated with cognitive decline. However, despite the epidemiological link between diabetes and cognitive impairment there is a paucity of data on managing both conditions, and as a result, a lack of guideline implementation.

Current guidance

The limited data on this comorbidity have led to current guidance being based on consensus statements and common sense approaches that focus on relaxing targets and avoiding hypoglycemia via the simplification of regimens. However, to date, there has not been a single study that has looked into the practical aspects of managing of patients with diabetes and dementia. Guidelines issued by organizations such as the American Diabetes Association (ADA), International Diabetes Federation (IDF) and various other working groups do not utilize robust evidence in practice. Rather, they rely on best practice discussion among specialists. It is therefore imperative that future trials are directed towards this area of diabetes care.

Focus of clinical care

There is a clear need for specific focus and understanding in this area due to the complexity of managing patients exhibiting both diabetes and dementia. As always, individualized care is key; however, there are similar trends that are common to patients with both conditions. For instance, a degree of cognitive decline can be expected as patients with diabetes approach old age. In line with these changes, diabetes self-management and awareness can become impaired, potentially leading to poorer adherence and greater reliance on carers/family, regardless of the type of diabetes or treatment employed.

 While the focus of diabetes management in older adults tends to be based around the avoidance of hypoglycemia, care must be taken to ensure that medications are optimized, and HbA1c targets (even if lax) are achieved to avoid osmotic symptoms and complications, including hyperosmolar hyperglycemic state or diabetic ketoacidosis.

Editor's recommendation
Pill in hand (symbolic image with model)

02-13-2018 | Older adults | Editorial | Article

Does setting treatment targets risk the overtreatment of type 2 diabetes in older patients?

The drive to achieve lower HbA1c targets in older patients is not without concern or risk. Our UK Board address concerns highlighted by recent trials and discuss whether current guidelines do enough to mitigate the risks of overtreatment.

Guidance on managing patients with diabetes and dementia is mixed. Some larger societies such as the ADA and IDF have specific sections of guidance covering dementia; however, in the UK there is no specific guidance. Currently, there are two key documents that address the issue of diabetes and dementia: specifically the TREND-UK and Institute for Diabetes in Old People (IDOP) guidance. TREND-UK provides practical guidance on managing patients and a working group position statement has also looked at managing patients with both conditions. However, this has been superseded by the IDOP guidelines released in 2017, which deal with frailty in diabetes but also address dementia. A general recommendation given by all three organizations is to aim for an HbA1c between 7% and 8% (53–64 mmol/mol) with further relaxation in advanced and frailer cases (see table below). The focus is on hypoglycemia avoidance and improving life through the adoption of simpler regimens.

HbA1c target recommendations from leading organizations and working groups


HbA1c target

Fasting target

Postprandial target

International Diabetes Federation. Managing Older People With Type 2 Diabetes: Global Guideline (2012)


(70 mmol/mol)

Diabetes UK. Good Clinical Practice Guidelines for Care Home Residents with Diabetes. A revision document prepared by a Task and Finish Group of Diabetes UK (2010).

7–8% (53–64 mmol/mol)

7–8.5 mmol/l

8–12 mmol/l

National Expert Working Group. Diabetes and dementia in older people: a best clinical practice statement (2014)

7–8% (53–64 mmol/mol)

6–9 mmol/l

American Diabetes Association. Mild-moderate cognitive impairment (2019)

<8% (64 mmol/mol)

90–150 mg/dl (5–8.3 mmol/l)

100–180 mg/dl (5.5–10 mmol/l) bedtime

American Diabetes Association. Moderate-severe cognitive impairment (2019)

<8.5% (70 mmol/mol)

100–180 mg/dl (5.5–10 mmol/l)

110–200 mg/dl (6.1–11.6 mmol/l)

HbA1c=glycated hemoglobin.

Reproduced with permission of the editors, British Journal of Diabetes: Management of diabetes and dementia. Puttanna A, Padinjakara N. British Journal of Diabetes 2017; 17: 93–99. doi:10.15277/bjd.2017.139

Practical management for healthcare teams

The first step toward achieving better outcomes in individuals with diabetes and dementia must be increased awareness and acknowledgement of this population and their complex care needs.

In teams that are better educated about diabetes and dementia, active case finding in both primary and secondary care becomes possible, enabling preventative measures to be taken rather than relying solely on reactive interventions. Within primary care, opportunities include assessing coded patients with both conditions, or placing specific focus on care home populations. In the secondary care setting, involvement of the dementia specialist team or nurse and/or the gerontology team allows for further case finding and liaison with diabetes teams. Patients with both diabetes and dementia need a focused and structured assessment, which should result in the production of an individualized management plan.

Determining glycemic target

Assessment must include: a recent HbA1c and/or recent blood sugar readings (depending on whether or not insulin has been prescribed); assessment of self-management skills; who the main carers are (if any); and, caloric intake. Further assessment of hypoglycemia risk, vascular and foot risk, and risk of other complications as well as trends in glycemic control will support the development of a management plan. A target HbA1c and glycemic range should be determined, which will vary in intensity depending on a patient’s life expectancy, self-care needs, comorbidities and expectations (including those of carers or family). It is important that in those with limited self-management skills, carers and family are involved and made aware of the plans.

Editor's recommendation
Checking blood sugar

05-02-2018 | Insulin | Editorial | Article

Glycemic goal setting in type 1 diabetes: Time to get SMART in the clinic?

Diabetes and endocrinology Consultant and Advisory Board member Terence Pang highlights the benefits that a structured approach to glycemic goal setting can bring to your practice and patients with type 1 diabetes.

Type 1 diabetes

Patients with type 1 diabetes can also benefit from assessment of insulin doses to avoid inappropriate dosing with variable caloric intake. With irregular eating patterns, insulin administration may need to be delayed or reduced depending on the amount eaten. This is a developing area with further research needs. Though not specifically for those with cognitive impairment, recent articles have suggested management considerations for the frail older adult with type 1 diabetes.

Medication choice in yype 2 diabetes

Patients with type 2 diabetes and dementia need appropriate medication regimens, which should focus on simplification and lower hypoglycemia risk as these individuals are a particularly vulnerable group. The balance between reducing risk and hyperglycemia can prove tricky and the risk of rebound hyperglycemia must be considered when de-intensification is considered.

To date, no medication has demonstrated a definite benefit in terms of cognitive improvement in patients with established dementia. However, pioglitazone and some glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have shown potential in cognitive impairment. Current management should address the previously mentioned issues together with the side effect profile and safety of each class of medications. The table below provides an overview of benefits and risks of each medicine class in patients with diabetes and dementia.


Benefits of use

Risks of use


Low risk hypoglycaemia, well tolerated

Risk in renal impairment (dehydration), gastrointestinal side effects, comorbidities can limit use


Quick glucose stabilisation, relatively well tolerated

Increased risk of hypoglycaemia, especially if comorbidities, risk of heart failure


Useful but limited glycaemic control

Long-term effects (cardiovascular/bladder/fracture risk)


Rapid insulin promoting action, useful in erratic eaters, possible lower risk hypoglycaemia

Limited availability, cost

DPP-4 inhibitors

Benefit especially in renal impairment, low risk hypoglycaemia

Moderate glycaemic improvement

GLP-1 agonists

Low risk hypoglycaemia, good glycaemic improvement

Weight loss may not be ideal, satiety effects not ideal, gastrointestinal side effects, cost benefit, may not be effective at late stage

SGLT-2 inhibitors

Good glycaemic improvement but avoid

Risk of dehydration, UTIs/thrush and confusion, comorbidities limit use

UTI=urinary tract infection. Reproduced with permission of the editors, British Journal of Diabetes: Management of diabetes and dementia. Puttanna A, Padinjakara N. British Journal of Diabetes 2017; 17: 93–99. doi:10.15277/bjd.2017.139

Future considerations

Despite the knowledge that there is a link between both conditions, there are still limited clinical data regarding management of people with diabetes and dementia. This is partly being addressed by the DIADEM project in the West Midlands.

The impact of medication and diabetes management on cognitive function and risks of medications in those with cognitive dysfunction need to be further investigated. There is some work with GLP-1 RAs on patients with cognitive impairment, however we will have to wait before large-scale studies include cognitive performance as part of their data collection, despite the fact that this is sorely needed.

Useful resources to share with patients and carers

Novel clinical evidence in continuous glucose monitoring

Novel clinical evidence in continuous glucose monitoring

How real-world studies complement randomized controlled trials

Jean-Pierre Riveline uses data from real-life continuous glucose monitoring studies to illustrate how these can uncover critical information about clinical outcomes that are hard to assess in randomized controlled trials.

This video has been developed through unrestricted educational funding from Abbott Diabetes Care.

Watch the video